Expression and In Vivo rescue of human ABCC6 disease-causing mutants in mouse liver

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Le Saux, Olivier ^a   Fülöp, Krisztina ^b   Yamaguchi, Yukiko ^a   Iliás, Attila ^b   Szabó, Zalán ^b   Brampton, Christopher N ^a   Pomozi, Viola ^b   Huszár, Krisztina ^b   Arányi, Tamás ^b   Váradi, András ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b INSTITUTE OF ENZYMOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ABC TRANSPORTER; ABCC6 PROTEIN; UNCLASSIFIED DRUG; ABCC6 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LIVER CELL; MISSENSE MUTATION; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN TRANSPORT; ANIMAL; GENETICS; HUMAN; LIVER; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL;

MUS;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LIVER; MICE; MICE, TRANSGENIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION;

EID: 80052827583     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024738     Document Type: Article

References (53)

1. Aherrahrou Z, Doehring LC, Ehlers EM, Liptau H, Depping R, et al. (2008) An alternative splice variant in Abcc6, the gene causing dystrophic calcification, leads to protein deficiency in C3H/He mice. J Biol Chem 283: 7608-7615.
2. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, et al. (2000) Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 25: 228-231.
3. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, et al. (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 25: 223-227.
4. Meng H, Vera I, Che N, Wang X, Wang SS, et al. (2007) Identification of Abcc6 as the major causal gene for dystrophic cardiac calcification in mice through integrative genomics. Proc Natl Acad Sci U S A 104: 4530-4535.
5. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J, (2000) Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A 97: 6001-6006.
6. Varadi A, Szabo Z, Pomozi V, de Boussac H, Fulop K, et al. (2011) ABCC6 as a target in pseudoxanthoma elasticum. Curr Drug Targets 12: 671-682.
7. Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A, (2005) Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet 42: 881-892.
8. Li Q, Jiang Q, Pfendner E, Varadi A, Uitto J, (2009) Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Dermatol 18: 1-11.
9. Koblos G, Andrikovics H, Prohaszka Z, Tordai A, Varadi A, et al. (2010) The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease. Genet Test Mol Biomarkers 14: 75-78.
10. Martin L, Maitre F, Bonicel P, Daudon P, Verny C, et al. (2008) Heterozygosity for a single mutation in the ABCC6 gene may closely mimic PXE: consequences of this phenotype overlap for the definition of PXE. Arch Dermatol 144: 301-306.
11. Trip MD, Smulders YM, Wegman JJ, Hu X, Boer JM, et al. (2002) Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. Circulation 106: 773-775.
12. de Boussac H, Ratajewski M, Sachrajda I, Koblos G, Tordai A, et al. (2010) The ERK1/2-hepatocyte nuclear factor 4alpha axis regulates human ABCC6 gene expression in hepatocytes. J Biol Chem 285: 22800-22808.
13. Aranyi T, Ratajewski M, Bardoczy V, Pulaski L, Bors A, et al. (2005) Identification of a DNA methylation-dependent activator sequence in the pseudoxanthoma elasticum gene, ABCC6. J Biol Chem 280: 18643-18650.
14. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, et al. (2002) Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem 277: 16860-16867.
15. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD, (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62: 6172-6177.
16. Beck K, Hayashi K, Nishiguchi B, Le Saux O, Hayashi M, et al. (2003) The distribution of Abcc6 in normal mouse tissues suggests multiple functions for this ABC transporter. J Histochem Cytochem 51: 887-902.
17. Beck K, Hayashi K, Dang K, Hayashi M, Boyd CD, (2005) Analysis of ABCC6 (MRP6) in normal human tissues. Histochem Cell Biol 123: 517-528.
18. Le Saux O, Bunda S, VanWart CM, Douet V, Got L, et al. (2006) Serum factors from pseudoxanthoma elasticum patients alter elastic fiber formation in vitro. J Invest Dermatol 126: 1497-1505.
19. Jiang Q, Endo M, Dibra F, Wang K, Uitto J, (2009) Pseudoxanthoma elasticum is a metabolic disease. J Invest Dermatol 129: 348-354.
20. Jiang Q, Oldenburg R, Otsuru S, Grand-Pierre AE, Horwitz EM, et al. (2010) Parabiotic heterogenetic pairing of Abcc6-/-/Rag1-/- mice and their wild-type counterparts halts ectopic mineralization in a murine model of pseudoxanthoma elasticum. Am J Pathol 176: 1855-1862.
21. Le Saux O, Beck K, Sachsinger C, Silvestri C, Treiber C, et al. (2001) A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum. Am J Hum Genet 69: 749-764.
22. Pfendner EG, Vanakker OM, Terry SF, Vourthis S, McAndrew PE, et al. (2007) Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J Med Genet 44: 621-628.
23. Fulop K, Barna L, Symmons O, Zavodszky P, Varadi A, (2009) Clustering of disease-causing mutations on the domain-domain interfaces of ABCC6. Biochem Biophys Res Commun 379: 706-709.
24. Rubenstein RC, Egan ME, Zeitlin PL, (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100: 2457-2465.
25. Rubenstein RC, Zeitlin PL, (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157: 484-490.
26. Rubenstein RC, Zeitlin PL, (2000) Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 278: C259-267.
27. Cheong N, Madesh M, Gonzales LW, Zhao M, Yu K, et al. (2006) Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem 281: 9791-9800.
28. Tveten K, Holla OL, Ranheim T, Berge KE, Leren TP, et al. (2007) 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. FEBS J 274: 1881-1893.
29. Hayashi H, Sugiyama Y, (2007) 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 45: 1506-1516.
30. Lam P, Pearson CL, Soroka CJ, Xu S, Mennone A, et al. (2007) Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol Cell Physiol 293: C1709-1716.
31. Hayashi H, Sugiyama Y, (2009) Short-chain ubiquitination is associated with the degradation rate of a cell-surface-resident bile salt export pump (BSEP/ABCB11). Mol Pharmacol 75: 143-150.
32. van den Berghe PV, Stapelbroek JM, Krieger E, de Bie P, van de Graaf SF, et al. (2009) Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin. Hepatology 50: 1783-1795.
33. van der Velden LM, Stapelbroek JM, Krieger E, van den Berghe PV, Berger R, et al. (2010) Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 51: 286-296.
34. Powell PD, Bellanne-Chantelot C, Flanagan SE, Ellard S, Rooman R, et al. (2011) In vitro recovery of ATP-sensitive potassium channels in beta-cells from patients with congenital hyperinsulinism of infancy. Diabetes 60: 1223-1228.
35. Dover GJ, Brusilow S, Samid D, (1992) Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 327: 569-570.
36. Maestri NE, Brusilow SW, Clissold DB, Bassett SS, (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335: 855-859.
37. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, et al. (1993) A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 328: 81-86.
38. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J, (2007) Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci 48: 1683-1690.
39. Szakacs G, Ozvegy C, Bakos E, Sarkadi B, Varadi A, (2001) Role of glycine-534 and glycine-1179 of human multidrug resistance protein (MDR1) in drug-mediated control of ATP hydrolysis. Biochem J 356: 71-75.
40. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA, (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267: 4854-4858.
41. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, et al. (1998) Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273: 32167-32175.
42. Sinko E, Ilias A, Ujhelly O, Homolya L, Scheffer GL, et al. (2003) Subcellular localization and N-glycosylation of human ABCC6, expressed in MDCKII cells. Biochem Biophys Res Commun 308: 263-269.
43. Liu F, Song Y, Liu D, (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258-1266.
44. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, et al. (2004) Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 11: 675-682.
45. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B, (2000) Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol 57: 634-641.
46. Uitto J, Li Q, Jiang Q, (2010) Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Invest Dermatol 130: 661-670.
47. Bergen AA, (2006) Pseudoxanthoma elasticum: the end of the autosomal dominant segregation myth. J Invest Dermatol 126: 704-705.
48. Zhang G, Budker V, Wolff JA, (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10: 1735-1737.
49. Fernandez SB, Hollo Z, Kern A, Bakos E, Fischer PA, et al. (2002) Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells. J Biol Chem 277: 31048-31055.
50. Garcia-Mata R, Gao YS, Sztul E, (2002) Hassles with taking out the garbage: aggravating aggresomes. Traffic 3: 388-396.
51. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, et al. (1999) Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 145: 481-490.
52. Hollande E, Salvador-Cartier C, Alvarez L, Fanjul M, (2005) Expression of a wild-type CFTR maintains the integrity of the biosynthetic/secretory pathway in human cystic fibrosis pancreatic duct cells. J Histochem Cytochem 53: 1539-1552.
53. Tusnady GE, Sarkadi B, Simon I, Varadi A, (2006) Membrane topology of human ABC proteins. FEBS Lett 580: 1017-1022.